Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Obsessive-Compulsive Disorder

In brief

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Key facts

Study ID

NCT05940324

Run by

Stanford University

People needed

150

Starts

2024-02-24

Expected to finish

2028-11-01

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages 18-65
• Meet the criteria for OCD diagnosis
• Failed at least 1 prior trial of standard first-line OCD treatment
• Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
• Able to provide informed consent

You may not qualify if…

• prior naltrexone or ketamine use/exposure
• Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
• Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
• the presence of metal in the body that is contraindicated for MRI scans
• Eligibility Criteria for Healthy Volunteers:
• Inclusion Criteria:
• Ages 18-65
• Able to provide informed consent
• Exclusion Criteria:
• current or past use of psychotropic medication
• pregnant or nursing females
• the presence of metal in the body that is contraindicated for MRI scans

Where it is running

• Department of Psychiatry & Behavioral Sciences — Stanford, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.